:FDANIR-II,pH,

Guanjun Deng1, Siwei Zhang2, Xinghua Peng1

  • 1Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen 518055, P.R. China.

PubMed
概括

甲蓝 (MB) 是FDA批准的药物,在质子化时转移到NIR-II窗口并表现出聚合诱导排放 (AIE). 这种转换使得在非常低的pH值下能够有效地进行过血症成像.